Biosimilars Council calls for more efficient regulatory pathways for critical medicines

A new position paper shows streamlining the approval process will foster advantages for patients, drug manufacturers and the FDA.

Related Keywords

United States ,Craig Burton ,Biosimilars Council ,Drug Administration ,Association For Accessible Medicines ,Accessible Medicines ,Biologics Price Competition ,Innovation Act ,Patient Protection ,Affordable Care ,